SFM
BLACR

Spartan Fund Management’s Bellevue Life Sciences Acquisition Corp. Rights BLACR Stock Holding History

Spartan Fund Management’s Portfolio BLACR Stock Details BLACR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-69,076
Closed -$9.88K – 110
2024
Q1 		$9.88K Sell
69,076
-89,400
-56% -$13.7K 0.02% 71
2023
Q4 		$28.1K Sell
158,476
-41,524
-21% -$6.71K 0.03% 87
2023
Q3 		$56K Sell
200,000
-30,528
-13% -$6.02K 0.04% 113
2023
Q2 		$92K Buy
+230,528
New +$40.1K 0.02% 156

Other funds holding BLACR

HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ASM
ATW SPAC Management New York $79.2M AUM 10.67% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Spartan Fund Management's BLACR Position: Q2 2024 in Review

Spartan Fund Management sold out of Bellevue Life Sciences Acquisition Corp. Rights (BLACR) in Q2 2024, closing a stake of 69,076 shares — an estimated $9.88K sold.

Spartan Fund Management first reported a position in BLACR in Q2 2023 and held it in 4 quarters. The position peaked at $92K in Q2 2023. 30 funds tracked by Wall St. Rank hold BLACR as of Q2 2024.

  • Spartan Fund Management reported no remaining Bellevue Life Sciences Acquisition Corp. Rights position as of Q2 2024 after selling out during the quarter.
  • Spartan Fund Management sold 69,076 Bellevue Life Sciences Acquisition Corp. Rights shares in Q2 2024, an estimated $9.88K.
  • Spartan Fund Management first reported a position in Bellevue Life Sciences Acquisition Corp. Rights in Q2 2023 and held it in 4 quarters.
  • Spartan Fund Management's Bellevue Life Sciences Acquisition Corp. Rights position peaked at $92K in Q2 2023.
  • 30 funds tracked by Wall St. Rank held Bellevue Life Sciences Acquisition Corp. Rights as of Q2 2024.

Based on Spartan Fund Management's 13F filing for Q2 2024, filed 31 Jul 2024.